R-DHAOx regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of rituximab, dexamethasone, high-dose cytarabine|cytarabine (Ar..." |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[dexamethasone]], high-dose [[cytarabine|cytarabine (Ara-C)]], and [[oxaliplatin]] (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with [[follicular non-Hodgkin's lymphoma]].<ref name="pmid20044233">{{cite journal| author=Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N et al.| title=Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. | journal=Biomed Pharmacother | year= 2010 | volume= 64 | issue= 2 | pages= 83-7 | pmid=20044233 | doi=10.1016/j.biopha.2009.11.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20044233 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[dexamethasone]], high-dose [[cytarabine|cytarabine (Ara-C)]], and [[oxaliplatin]] (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with [[follicular non-Hodgkin's lymphoma]].<ref name="pmid20044233">{{cite journal| author=Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N et al.| title=Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. | journal=Biomed Pharmacother | year= 2010 | volume= 64 | issue= 2 | pages= 83-7 | pmid=20044233 | doi=10.1016/j.biopha.2009.11.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20044233 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | |||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
| Line 14: | Line 13: | ||
{{chemo|A|Cytarabine (Ara-C)}} | {{chemo|A|Cytarabine (Ara-C)}} | ||
{{chemo|Ox|Oxaliplatin}} | {{chemo|Ox|Oxaliplatin}} | ||
==Indications== *[[Follicular non-Hodgkin's lymphoma]]<ref name="pmid20044233">{{cite journal| author=Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N et al.| title=Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. | journal=Biomed Pharmacother | year= 2010 | volume= 64 | issue= 2 | pages= 83-7 | pmid=20044233 | doi=10.1016/j.biopha.2009.11.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20044233 }} </ref> | |||
==Indications== | |||
*[[Follicular non-Hodgkin's lymphoma]]<ref name="pmid20044233">{{cite journal| author=Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N et al.| title=Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. | journal=Biomed Pharmacother | year= 2010 | volume= 64 | issue= 2 | pages= 83-7 | pmid=20044233 | doi=10.1016/j.biopha.2009.11.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20044233 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 16:53, 31 March 2015
|
WikiDoc Resources for R-DHAOx regimen |
|
Articles |
|---|
|
Most recent articles on R-DHAOx regimen Most cited articles on R-DHAOx regimen |
|
Media |
|
Powerpoint slides on R-DHAOx regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-DHAOx regimen at Clinical Trials.gov Trial results on R-DHAOx regimen Clinical Trials on R-DHAOx regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-DHAOx regimen NICE Guidance on R-DHAOx regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-DHAOx regimen Discussion groups on R-DHAOx regimen Patient Handouts on R-DHAOx regimen Directions to Hospitals Treating R-DHAOx regimen Risk calculators and risk factors for R-DHAOx regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-DHAOx regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
R-DHAOx regimen refers to a regimen consisting of rituximab, dexamethasone, high-dose cytarabine (Ara-C), and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.[1]
Regimen
RRituximab
DDexamethasone
HHigh Dose
ACytarabine (Ara-C)
OxOxaliplatin
Indications
References
- ↑ 1.0 1.1 Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N; et al. (2010). "Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma". Biomed Pharmacother. 64 (2): 83–7. doi:10.1016/j.biopha.2009.11.001. PMID 20044233.